Pharmacological smoking cessation of adults aged 30–50 years with COPD
Abstract The prevalence of active smokers has remained relatively stable around 20% for several years in Denmark despite knowledge of the harmful effects. Smoking cessation is the most effective way to limit progression and reduce mortality of chronic obstructive pulmonary disease (COPD). Therefore,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-10-01
|
| Series: | npj Primary Care Respiratory Medicine |
| Online Access: | https://doi.org/10.1038/s41533-022-00301-y |
| _version_ | 1817984820952694784 |
|---|---|
| author | Dea Kejlberg Andelius Ole Hilberg Rikke Ibsen Anders Løkke |
| author_facet | Dea Kejlberg Andelius Ole Hilberg Rikke Ibsen Anders Løkke |
| author_sort | Dea Kejlberg Andelius |
| collection | DOAJ |
| description | Abstract The prevalence of active smokers has remained relatively stable around 20% for several years in Denmark despite knowledge of the harmful effects. Smoking cessation is the most effective way to limit progression and reduce mortality of chronic obstructive pulmonary disease (COPD). Therefore, smoking cessation is particularly important among adults with COPD. The aim of this study was to determine the extent to which adults 30–50 years of age with COPD redeem pharmacotherapy for smoking cessation, and to identify demographic factors that influence the use of smoking cessation medication. We conducted a national retrospective non-interventional registry study, including all Danish patients with COPD (ICD-10 code J.44: chronic obstructive pulmonary disease) aged 30–50 years in the period 2009–2015. We identified 7734 cases, who were matched with controls (15,307) 1:2 on age, sex, and geography. Smoking status was not registered. We found that 18% of cases (with an estimated smoking prevalence at 33–50%) redeemed pharmacological smoking cessation medication in the study period compared to 3% of the controls (with an estimated smoking prevalence at 23%). The OR for cases collecting pharmacological smoking cessation medication was 5.92 [95% CI 5.24–6.70]. Male sex, being unemployed, and receiving social benefits were factors associated with less probability of redeeming pharmacological smoking cessation medication. Our study indicates that attention is needed on smoking cessation in adults aged 30–50 years with COPD, especially if unemployed or receiving social benefits, as these individuals are less likely to redeem pharmacological smoking cessation medication. |
| first_indexed | 2024-04-13T23:50:19Z |
| format | Article |
| id | doaj.art-d59578d08c3944738b4e9877cdfe2879 |
| institution | Directory Open Access Journal |
| issn | 2055-1010 |
| language | English |
| last_indexed | 2024-04-13T23:50:19Z |
| publishDate | 2022-10-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Primary Care Respiratory Medicine |
| spelling | doaj.art-d59578d08c3944738b4e9877cdfe28792022-12-22T02:24:08ZengNature Portfolionpj Primary Care Respiratory Medicine2055-10102022-10-013211710.1038/s41533-022-00301-yPharmacological smoking cessation of adults aged 30–50 years with COPDDea Kejlberg Andelius0Ole Hilberg1Rikke Ibsen2Anders Løkke3Research Unit for General PracticeDepartment of Medicine, Little Belt Hospitali2mindsDepartment of Medicine, Little Belt HospitalAbstract The prevalence of active smokers has remained relatively stable around 20% for several years in Denmark despite knowledge of the harmful effects. Smoking cessation is the most effective way to limit progression and reduce mortality of chronic obstructive pulmonary disease (COPD). Therefore, smoking cessation is particularly important among adults with COPD. The aim of this study was to determine the extent to which adults 30–50 years of age with COPD redeem pharmacotherapy for smoking cessation, and to identify demographic factors that influence the use of smoking cessation medication. We conducted a national retrospective non-interventional registry study, including all Danish patients with COPD (ICD-10 code J.44: chronic obstructive pulmonary disease) aged 30–50 years in the period 2009–2015. We identified 7734 cases, who were matched with controls (15,307) 1:2 on age, sex, and geography. Smoking status was not registered. We found that 18% of cases (with an estimated smoking prevalence at 33–50%) redeemed pharmacological smoking cessation medication in the study period compared to 3% of the controls (with an estimated smoking prevalence at 23%). The OR for cases collecting pharmacological smoking cessation medication was 5.92 [95% CI 5.24–6.70]. Male sex, being unemployed, and receiving social benefits were factors associated with less probability of redeeming pharmacological smoking cessation medication. Our study indicates that attention is needed on smoking cessation in adults aged 30–50 years with COPD, especially if unemployed or receiving social benefits, as these individuals are less likely to redeem pharmacological smoking cessation medication.https://doi.org/10.1038/s41533-022-00301-y |
| spellingShingle | Dea Kejlberg Andelius Ole Hilberg Rikke Ibsen Anders Løkke Pharmacological smoking cessation of adults aged 30–50 years with COPD npj Primary Care Respiratory Medicine |
| title | Pharmacological smoking cessation of adults aged 30–50 years with COPD |
| title_full | Pharmacological smoking cessation of adults aged 30–50 years with COPD |
| title_fullStr | Pharmacological smoking cessation of adults aged 30–50 years with COPD |
| title_full_unstemmed | Pharmacological smoking cessation of adults aged 30–50 years with COPD |
| title_short | Pharmacological smoking cessation of adults aged 30–50 years with COPD |
| title_sort | pharmacological smoking cessation of adults aged 30 50 years with copd |
| url | https://doi.org/10.1038/s41533-022-00301-y |
| work_keys_str_mv | AT deakejlbergandelius pharmacologicalsmokingcessationofadultsaged3050yearswithcopd AT olehilberg pharmacologicalsmokingcessationofadultsaged3050yearswithcopd AT rikkeibsen pharmacologicalsmokingcessationofadultsaged3050yearswithcopd AT andersløkke pharmacologicalsmokingcessationofadultsaged3050yearswithcopd |